RxDoctor Payments Data

Tina Jones, MD

Internal Medicine · Smyrna, GANPI 1730147117

Payments from drug & device makers

$2,051in general payments, 2019–2025

Across 59 payments — averaging $34.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$639
  • Novo Nordisk$457
  • Lilly USA, LLC$389
  • Amgen$122
  • Boehringer Ingelheim$118
  • Merck$100
  • plus $225 from 6 others

What the payments were for

  • Travel & lodging$100%
  • Food & beverage$2,041100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,051 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$14,039
Medicare patients
49
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$70,676
MounjaroTirzepatide34$39,978
JardianceEmpagliflozin36$37,278
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,821
FarxigaDapagliflozin Propanediol12$14,166
Breo ElliptaFluticasone/Vilanterol15$12,956
SynthroidLevothyroxine Sodium30$2,719
Atorvastatin Calcium200$1,443
Nebivolol Hcl19$1,376
Rosuvastatin Calcium89$1,263
Olmesartan Medoxomil59$1,216
Metoprolol Succinate44$1,005
Losartan Potassium96$941
Amlodipine Besylate182$909
Fluticasone Propionate36$856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$457$70,67648 claims
Lilly USA, LLCMounjaro$389$39,97834 claims
Boehringer IngelheimJardiance$118$37,27836 claims
AstraZenecaFarxiga$639$14,16612 claims
AbbVieSynthroid$41$2,71930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →